Aridis to delist from Nas­daq; Bi­cy­cle clos­es $200M+ of­fer­ing

Aridis Phar­ma­ceu­ti­cals is be­ing tak­en off the Nas­daq, ef­fec­tive Wednes­day.

The biotech re­port­ed the news in an SEC fil­ing Mon­day, say­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.